Clinical Research & Publications
In 1998, light-scattering aggregometry was developed to assess platelet function and activity by scientists at Brigham Young University and the University of Utah, in association with the Utah Artificial Heart Institute. The technology was protected by patent activity in the US and worldwide.
AggreDyne has commercialized this technology as the AggreGuide A-100 to help clinicians guide platelet therapy by finding if a platelet therapy is working.
The AggreGuide A-100 platelet function analyzer measures platelet aggregation using a patented light-scattering technology. A laser beam is directed into the disposable cartridge where the blood sample is mixed with the selected reagent agonist. The system identifies platelet aggregation by measuring light-scattering against the background of other components of the whole blood.
With the A-100 system, a small sample of unprocessed whole blood from a standard blue top tube (citrate) is simply added to the disposable test cartridge that contains the freeze-dried test reagent. The system automatically conducts the test, and in a few minutes the results are displayed on the A-100 screen.
The numerical result is termed “Platelet Activity Index”, abbreviated “PAI”, and gives an indication of the relative tendency of an individual’s platelets to aggregate.
Clinically, in determining whether or not an anti-platelet drug is working appropriately to cause platelet dysfunction in a patient, the PAI value is compared to a “cut-point” value. If the observed PAI is below the cut-point, then the determination is made that platelet dysfunction exists. If the observed PAI is above the cut-point, then the determination is made that platelet dysfunction is absent. The presence or absence of platelet dysfunction is information that is otherwise not available to the clinician.